Acute renal dysfunction in liver diseases

被引:87
作者
Betrosian, Alex P.
Agarwal, Banwari
Douzinas, Emmanuel E.
机构
[1] Univ Athens, Evgenidion Hosp, Dept Crit Care 3, GR-11528 Athens, Greece
[2] Royal Free Hosp, Intens Theraphy Unit, London NW3 2QG, England
关键词
hepatorenal syndrome; transjugular intrahepatic portosystemic shunt; continuous renal replacement therapy; molecular absorbent recirculating system; acute liver failure; systemic vascular resistance; renal blood flow;
D O I
10.3748/wjg.v13.i42.5552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Renal dysfunction is common in liver diseases, either as part of multiorgan involvement in acute illness or secondary to advanced liver disease. The presence of renal impairment in both groups is a poor prognostic indicator. Renal failure is often multifactorial and can present as pre-renal or intrinsic renal dysfunction. Obstructive or post renal dysfunction only rarely complicates liver disease. Hepatorenal syndrome (HRS) is a unique form of renal failure associated with advanced liver disease or cirrhosis, and is characterized by functional renal impairment without significant changes in renal histology. Irrespective of the type of renal failure, renal hypoperfusion is the central pathogenetic mechanism, due either to reduced perfusion pressure or increased renal vascular resistance. Volume expansion, avoidance of precipitating factors and treatment of underlying liver disease constitute the mainstay of therapy to prevent and reverse renal impairment. Splanchnic vasoconstrictor agents, such as terlipressin, along with volume expansion, and early placement of transjugular intrahepatic portosystemic shunt (TIPS) may be effective in improving renal function in HRS. Continuous renal replacement therapy (CRRT) and molecular absorbent recirculating system (MARS) in selected patients may be life saving while awaiting liver transplantation. (c) 2007 WJG. All rights reserved.
引用
收藏
页码:5552 / 5559
页数:8
相关论文
共 70 条
[1]   Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature [J].
Abraham, KA ;
Kennelly, M ;
Dorman, AM ;
Walshe, JJ .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2003, 108 (01) :99-102
[2]  
[Anonymous], TXB NEPHROLOGY
[3]  
Arroyo, 2004, ALIMENT PHARM THER, V20, P55
[4]  
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[5]   Hepatorenal syndrome - how to assess response to treatment and nonpharmacological therapy [J].
Arroyo, V .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 :49-54
[6]  
ARROYO V, 2005, OXFORD TXB CLIN HEPA, P1564
[7]   PREVENTION OF NEPHROTOXICITY INDUCED BY RADIOCONTRAST AGENTS [J].
BARRETT, BJ ;
PARFREY, PS .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (21) :1449-1450
[8]   Hepatorenal syndrome [J].
Bataller, R ;
Ginès, P ;
Guevara, M ;
Arroyo, V .
SEMINARS IN LIVER DISEASE, 1997, 17 (03) :233-247
[9]  
Bellomo R, 2000, LANCET, V356, P2139
[10]   HEPATORENAL DISORDERS - ROLE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM [J].
BERNARDI, M ;
TREVISANI, F ;
GASBARRINI, A ;
GASBARRINI, G .
SEMINARS IN LIVER DISEASE, 1994, 14 (01) :23-34